Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient ...

Tempus AI (TEM) has recently been in the spotlight after raising its earnings guidance and reporting a substantial improvement in its financial results for Q2 2025, with revenue jumping from a year ...

Tempus AI (NASDAQ:TEM) surged 9% in premarket trading on Friday after the genetic testing company posted a ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this ...

Shares in health technology group Tempus AI ($TEM) raced 7% higher today after its Q2 revenues surged on cancer testing ...

In trading on the Nasdaq stock market as of 1:17 p.m. Central, Tempus' stock price was trading at $60.65, up 3.2% from the ...

Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in ...

Analysts expect the Chicago, Illinois-based company to report a quarterly loss at 25 cents per share, versus a year-ago loss ...

Tempus AI (NASDAQ:TEM) surged 9% in premarket trading Friday after the genetic testing firm reported a second-quarter loss per share of $0.22, better than the $0.25 loss expected by analysts.

Shares of Tempus AI climbed after the company narrowed its net loss and logged higher-than-expected revenue in the second quarter, boosted by what Chief Executive Eric Lefkofsky called a significant ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

Q2 2025 Earnings Conference Call August 8, 2025 8:00 PM ETCompany ParticipantsElizabeth Krutoholow - Vice President of ...